These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31390185)

  • 1. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
    Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
    ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
    Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
    ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
    Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
    Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cyclized Helix-Loop-Helix Peptide as a Molecular Scaffold for the Design of Inhibitors of Intracellular Protein-Protein Interactions by Epitope and Arginine Grafting.
    Fujiwara D; Kitada H; Oguri M; Nishihara T; Michigami M; Shiraishi K; Yuba E; Nakase I; Im H; Cho S; Joung JY; Kodama S; Kono K; Ham S; Fujii I
    Angew Chem Int Ed Engl; 2016 Aug; 55(36):10612-5. PubMed ID: 27467415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties.
    Partridge AW; Kaan HYK; Juang YC; Sadruddin A; Lim S; Brown CJ; Ng S; Thean D; Ferrer F; Johannes C; Yuen TY; Kannan S; Aronica P; Tan YS; Pradhan MR; Verma CS; Hochman J; Chen S; Wan H; Ha S; Sherborne B; Lane DP; Sawyer TK
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31226791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
    Sang P; Shi Y; Lu J; Chen L; Yang L; Borcherds W; Abdulkadir S; Li Q; Daughdrill G; Chen J; Cai J
    J Med Chem; 2020 Feb; 63(3):975-986. PubMed ID: 31971801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
    Rosal R; Pincus MR; Brandt-Rauf PW; Fine RL; Michl J; Wang H
    Biochemistry; 2004 Feb; 43(7):1854-61. PubMed ID: 14967026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
    Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
    Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
    Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
    Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
    J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
    Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
    Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
    Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
    Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.